To determine the cost of Rystiggo, it's important to consider its pricing structure and potential financial assistance programs, as exact figures can vary.
What is the list price of Rystiggo?
The list price for Rystiggo (rizstegrist) is $7,160 for a 30-day supply [1]. This price reflects the drug's development and manufacturing costs.
Are there programs to help with the cost of Rystiggo?
Yes, Takeda Pharmaceuticals, the manufacturer, offers programs to assist eligible patients with the cost of Rystiggo. These programs may include co-pay savings cards for commercially insured patients, which can reduce out-of-pocket expenses to as low as $0 per prescription for up to 12 months [1]. For patients facing financial hardship and without insurance, Takeda also provides the Takeda membantu program, which offers free medication to eligible individuals [1].
How is Rystiggo priced compared to other treatments?
Rystiggo's pricing places it within the range of other high-cost specialty medications used to treat chronic and rare conditions. Comparisons with alternative treatments would need to consider not only the drug's list price but also the efficacy, administration route, and potential long-term healthcare costs associated with each therapy. Information on specific drug pricing and patent exclusivity can be found on DrugPatentWatch.com [2].
When does Rystiggo's patent expire?
Patent expiration dates are critical for understanding when generic or biosimilar alternatives might become available, potentially impacting drug pricing. Information regarding Rystiggo's patent status and expiration timelines can be accessed through resources like DrugPatentWatch.com [2].
What is Rystiggo used for?
Rystiggo is a prescription medication approved for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive. Generalized myasthenia gravis is a chronic, autoimmune neuromuscular disease characterized by weakness in voluntary muscles.
What are the key differences between Rystiggo and other gMG treatments?
Rystiggo is a neonatal Fc receptor (FcRn) blocker. It works by reducing the levels of disease-causing immunoglobulin G (IgG) antibodies. Other treatments for gMG may include immunosuppressants, acetylcholinesterase inhibitors, or plasma exchange, which work through different mechanisms to manage the disease. The choice of treatment often depends on the severity of the disease, antibody status, and individual patient factors.
What clinical trial data supports Rystiggo's effectiveness?
The effectiveness of Rystiggo was established in two pivotal Phase 3 clinical trials, JOYSTEP and WELNERVE. These studies demonstrated a statistically significant improvement in primary endpoints, such as the Myasthenia Gravis Activities of Daily Living (MG-ADL) score and the Quantitative Myasthenia Gravis (QMG) score, compared to placebo in adult patients with anti-AChR antibody-positive gMG [1].
What are the potential side effects of Rystiggo?
The most common side effects reported in clinical trials for Rystiggo include muscle pain, headache, diarrhea, and protein in the urine (proteinuria). Serious side effects can also occur, and patients should discuss potential risks with their healthcare provider [1].
Sources:
[1] https://www.rystiggo.com/
[2] https://drugpatentwatch.com/